Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition Daniel Principe, 2022, Cancers CrossRef
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer Elisa D'Agostino et al, 2024, Cancer Treatment Reviews CrossRef
Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort Daniel R. Principe et al, 2020, Scientific Reports CrossRef
Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer Ke Shen et al, 2022, Current Drug Targets CrossRef
Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer Sachin Sharma et al, 2023, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
Upregulation of miR-183-5p is responsible for the promotion of apoptosis and inhibition of the epithelial-mesenchymal transition, proliferation, invasion and migration of human endometrial cancer cells by downregulating Ezrin Hua Yan et al, 2018, International Journal of Molecular Medicine CrossRef
Dynamic monitoring and quantitative characterization of intracellular H2O2 content by using SERS based boric acid nanoprobe Wendai Cheng et al, 2020, Talanta CrossRef
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
Lucia Musacchio et al, 2020, Cancer Management and Research CrossRef
Molecular Targeted Therapy in Endometrial Cancer: Basis and Therapeutics Shruti Bhatia et al, 2020, Recent Advances in Endometrial Cancer CrossRef
PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix Minakshi Mann et al, 2019, Oncotarget CrossRef